Introduction: Botulinum toxin injection is known to be efficient to treat achalasia. We
| INTRODUC TI ON
Distal esophageal spasm and jackhammer esophagus are both rare esophageal motility disorders, associated with esophageal symptoms including dysphagia and chest pain. Although the relaxation of the lower esophageal sphincter is normal in these two conditions, the pathophysiology may be close to achalasia, as it might imply a relative excess of cholinergic stimulation compared to the inhibitory nitrergic one, or an alteration of neural control.
1,2 Their diagnoses are based on esophageal manometry. The best definition of these conditions was provided with the version 3.0 of the Chicago Classification for esophageal high-resolution manometry (HRM).
3
Because of the potential similarities with regard to clinical symptoms, pathogenesis and potential treatments, we regrouped for this study under the term "hypercontractile esophagus" three rare esophageal motility disorders: type 3 achalasia, diffuse esophageal spasm, and jackhammer esophagus. As suggested by Kahrilas et al, 4 these three conditions may present with distal esophagus hypercontractility, responsible of obstructive esophageal contractions.
Its treatment remains challenging with a poor efficacy of pharmacologic treatment (nitrates, calcium channel blockers, sildenafil) and the lack of controlled studies. 5, 6 Botulinum toxin injection has been used for a long time for the treatment of achalasia, especially in older and frail patients 7, 8 and has also been proposed for the treatment of non-achalasia esophageal motor disorders. Indeed, several open-labeled studies have suggested a good efficacy of botulinum toxin to treat esophageal spasms or hypercontractile esophagus [9] [10] [11] [12] [13] and one randomized controlled study showed a significant short-term effect of botulinum toxin on dysphagia associated with diffuse esophageal spasms and nutcracker esophagus. 14 However, although the injection of botulinum toxin in digestive sphincters is considered to be a safe procedure, there may be adverse events including death. 15, 16 The evaluation of its efficacy and safety thus remains an important concern. 17 The aim of our study was to evaluate the efficacy of the botulinum toxin injection in the lower esophageal sphincter and the distal part of the esophageal body in patients with symptoms associated with hypercontractile esophagus as described by the Chicago classification v3.0. 
| PATIENTS AND ME THODS

| Patients
Patients from two tertiary centers (Lyon and Bordeaux University Hospitals, France) were included if they were older than 18 years, complained of dysphagia and/or non-cardiac chest pain for more than 6 months, with an Eckardt score ≥3/12. 18 Other inclusion criteria were a normal upper GI endoscopy during the previous 6 months, and no extrinsic compression at the barium esophagogram. 
| Study design
At inclusion, patients filled in standardized questionnaires (Eckardt score, 18 Swallow Sydney score 19 and Gastro-Intestinal Quality of Life 
Key points
• Botulinum toxin injection may be useful to treat esophageal hypercontractile motility disorders, but data are scarce in the literature. We tested the efficacy of this treatment through a randomized sham-controlled study.
• Twenty-three symptomatic patients selected on esophageal high-resolution manometry were included.
Symptomatic improvement was similar 3 and 12 months after botulinum toxin injection or sham procedure.
• Symptoms related to hypercontractile esophagus may improve spontaneously with time. This should be taken into account prior to propose new invasive endoscopic treatments.
were contacted by phone at 1 week to check for side effects. 
| Statistical analysis
The main objective of the study was to demonstrate a difference in clinical response at 3 months between the interventional and the sham groups. Clinical response was based on the Eckardt score and considered positive below 3. With an alpha risk of 10% and a beta risk of 20%, an expected placebo effect of 20% of responders in the sham group and an expected therapeutic effect of botulinum toxin of 70% of responders in the interventional group, the number of patients to be included was 14 per arm, or 28 subjects in total.
Data were expressed as median (interquartile range, IQR) unless otherwise indicated. Comparisons between groups were performed using Student t test, Khi 2 test, Mann-Whitney test, and one-way analysis of variance when appropriate. A P value <0.05 was considered as significant. Predictive factors of a positive response to botulinum toxin were tested by univariate analysis and then by logistic regression for the multivariate analysis. The overall evolution of the Eckardt, Sydney, and GIQLI scores (whatever the treatment arm) over time was modeled using linear mixed models. A linear trend over time was used for the Sydney and GIQLI scores, and a quadratic one was used for the Eckardt score. The random part of the models included a random intercept and slope by patient. 21 All authors had access to the study data and reviewed and approved the final manuscript.
| RE SULTS
Twenty-three patients (13 females), mean age 60 years (range 31-75),
were included between August 2013 and January 2017 (last followup January 2018). The inclusions in the trial were stopped despite the fact that the number of intended inclusions was not reached, because the inclusion period exceeded the expected duration for more than 12 months. Three cases did not fulfill the strict manometric criteria for type 3 achalasia and were included as atypical achalasia.
Eleven patients were randomized in the control group and 12 in the interventional group. One of the patients of the control group received erroneously the active treatment: We thus compared a sham group of 10 patients with an intervention group of 13 patients. The characteristics of the included patients are described in Table 1 .
Overall, there was a significant decrease of the Eckardt score at 1 and 3 months, but no difference between the interventional and sham groups (Figure 2 ). The response rate was not significantly Table 2 .
The Sydney swallow score and the GIQLI score were not significantly different at 3 months compared to baseline (mean difference of the Sydney score 71 (SD = 71), P = 0.33, mean difference of the GIQLI score: 2 (SD = 4), P = 0.65).
There were significant changes in manometric patterns 3 months after randomization, but these changes were independent of the received treatment (Table 3) . Among the 12 cases of jackhammer esophagus, there was a significant decrease of the esophageal con- F I G U R E 2 Evolution of the Eckardt score 3 months after randomization. There was a significant improvement of the score (*: P < 0.0001), but this improvement was independent of the allocated treatment (Botox: botulinum toxin injection) allocated treatment in this cohort of patients with a diagnosis of hypercontractile esophagus.
| D ISCUSS I ON
Our study was designed after we had a fatal case of mediastinitis after Botox® injection in the esophageal wall in a patient with DES. 15 As the literature is scarce on the subject, with only one randomized trial reported in patients with hypercontractile esophagus, it was important to confirm the efficacy of botulinum toxin injection in this particular indication. It was decided to perform a sham procedure in the control group (no injection) rather than saline injection because of a hypothetical infectious risk of substrate injection in the esophageal wall. Although no significant complication occurred in this series of patients, either after one or two injections of botulinum toxin, we believe that the risks of side effects (such as chest pain or heartburn), and the possibility of severe complication such as acute mediastinitis must be known by the physician and agreed by the patient before starting with this therapy. 16 Our randomized double-blind sham-controlled study yielded results somewhat different from the study reported by Vanuytsel et al 14 . In this latter study, the authors observed a significant improvement of dysphagia after botulinum toxin injection compared to saline injection. However, their evaluation was done on a very short term
(1 month after injection), because the control group received Botox® injection at 1 month during the follow-up. Interestingly, there was a similar decrease of the mean maximal distal amplitude of esophageal peristalsis at 1 and 2 months, whatever treatment patients received, botulinum toxin or saline first. This trend toward manometric improvement was also found in our study at 3 months, for at least 3 out of 10 patients that did not receive any treatment. This tendency toward a favorable evolution of hypercontractile esophagus (possible placebo effect, or spontaneous evolution of the disease) should be taken into account when evaluating the efficacy of new treatments.
Indeed, Schupack et al 22 found, in a cohort of 40 patients with a diagnosis of jackhammer esophagus (and 56 patients with a diagnosis of esophago-gastric junction outflow obstruction), that the majority of patients overall were asymptomatic at a mean 2.8 years follow-up, in the absence of a specific treatment. Per-oral endoscopic myotomy (POEM) is probably becoming the gold-standard treatment for achalasia, despite a potential risk for significant gastro-esophageal reflux disease. 23 They are now several case reports suggesting the efficacy of POEM to treat nutcracker or jackhammer esophagus and DES, including discussion as to whether cut or not the lower esophageal sphincter during the procedure. [24] [25] [26] [27] [28] [29] These promising results should be evaluated in the light of a possible spontaneous favorable evolution of these esophageal motility disorders and compared to sham procedure. In particular, the chronic use of opioids has been shown to induce hypercontractile esophageal motility disorders, that could improve with the decrease or cessation of the therapy. 30 Our study has several limitations. Firstly, the number of patients included is rather small: this may be an indicator that, even in expert centers, the prevalence of hypercontractile esophageal disorders associated with significant symptoms remains low. Secondly, the randomization process unfortunately produced unbalanced groups with regard to the manometric diagnoses. Indeed, the four cases of DES were randomized in the sham group, while 9 out 12 jackhammer F I G U R E 3 Evolution of esophageal high-resolution manometry at screening and 3 months after inclusion in the study. A, High-resolution manometry representation of two 5-mL swallows in the same patient, before and 3 months after injection of botulinum toxin. At baseline, the case was classified as atypical achalasia, with a shortening of the esophagus and pan-esophageal pressurization; 3 months later, esophageal contractions were classified as ineffective esophageal motility. B, High-resolution manometry representation of two 5-ml swallows in the same patient, before and 3 months after sham procedure. At baseline, the DCI was >8000 mm Hg.s.cm in 60% of swallows (jackhammer esophagus): 3 months later, esophageal contractions were normal (highest DCI: 7500 mm Hg.s.cm, with 90% of swallows with DCI < 4000 mm Hg.s.cm)
esophagus were included in the interventional arm. This unbalanced randomization may have prevented us to identify specific motor disorders that would be better candidates for botulinum toxin treatment. However, a previous retrospective study performed by our group failed to identify any manometric predictive factors of good response, while type 3 achalasia previously treated had the worst response. 31 Finally, despite the initial intention to include patients with well-characterized manometric disorders using HRM and the Chicago classification v3.0, some atypical manometric cases with bothering symptoms were included. Limits of the classification have been suggested and the addition of tests such as rapid drink challenge or ingestion of solids to improve the diagnostic ability of HRM.
32-34
In conclusion, this double-blind randomized sham-controlled study does not confirm the efficacy of botulinum toxin injection to improve the symptoms associated with hypercontractile esophageal motor disorders. The clinical symptoms associated with hypercontractile esophagus may improve spontaneously with time: Placebocontrolled studies are thus mandatory to evaluate new therapeutic protocols for these rare disorders. 
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